Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb 1;10(4):265-282.
doi: 10.2217/imt-2017-0136.

Emerging immune targets for the treatment of multiple myeloma

Atif Sohail  1 , Adeela Mushtaq  1 , Ahmad Iftikhar  1 , Zabih Warraich  1 , Sandra E Kurtin  1 , Pavan Tenneti  1 , Ali McBride  2 , Faiz Anwer  1
Affiliations

Emerging immune targets for the treatment of multiple myeloma

Atif Sohail et al. Immunotherapy. .

Abstract

We reviewed emerging immune strategies for multiple myeloma (MM) therapy excluding US FDA approved drugs. In relapsed refractory MM, isatuximab (anti-CD38) monotherapy achieved overall response (OR) of 24%. Other monoclonal antibodies that have shown efficacy in combination therapy include siltuximab (OR: 66%), indatuximab (OR: 78%), isatuximab (OR: 64.5%), pembrolizumab (OR: 60%), bevacizumab (OR: 70%), dacetuzumab (OR: 39%) and lorvotuzumab (OR: 56.4%). No OR was observed with monotherapy using BI-505, siltuximab, bevacizumab, AVE-1642, figitumumab, atacicept, milatuzumab, dacetuzumab, lucatumumab, IPH2101, lorvotuzumab, BT062 and nivolumab. We included seven clinical trials on chimeric antigen receptor (CAR) T cells. CAR T-cell targets include BCMA, CD19, KLC and CD138. A recent experience of CAR T-cell (B-cell maturation antigen) therapy in advanced MM has shown global response of 100%. The future of monoclonal antibodies and adoptive T cells for MM treatment seems promising.

Keywords: adoptive cell therapy; antibodies; antibody therapeutics; chimeric antigen T cells; immunotherapy; multiple myeloma.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

This work supported in part by grant P30 CA023074 from the National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.

Figures

<b>Figure 1.</b>
Figure 1.. Records identified through PubMed, Embase, Cochrane, Web of Science, Scopus and ClinicalTrials.gov database searches.
See this image and copyright information in PMC

References

    1. NIH NCI. Cancer stat facts: myeloma. https://seer.cancer.gov/statfacts/html/mulmy.html
    1. Society AC. Survival rates by stage for multiple myeloma. 2016. www.cancer.org/cancer/multiple-myeloma/detection-diagnosis-staging/survi...
    1. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26(1):149–157. - PMC - PubMed
    1. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat. Rev. Cancer. 2007;7(8):585–598. - PubMed
    1. Magarotto V, Salvini M, Bonello F, Bringhen S, Palumbo A. Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: a new era begins. Leuk. Lymphoma. 2016;57(3):537–556. - PubMed

    2. •• Elaborates role of elotuzumab and daratumumab and other antibodies, which are in preclinical or early clinical phases of evaluation for treatment of multiple myeloma (MM).

Publication types